CAS: 132-21-8; Dexbrompheniramine
该化合物是一种抗口炎,主要用于缓解鼻鼻鼻,喷水和痒等过敏症状;是溴苯胺的衍生物,具有解毒性配置,能提高其功效,并减少其与种族对应的副作用;通过阻塞H1肝胺受体,从而抑制过敏反应的化合物 ----丁胺 ----的生理影响;二溴苯丙胺通常是口服的,并可在各种配方中找到,包括药片和糖浆;它具有镇静性特性,可导致漂浮,使使用者在驾驶或操作机器时必须小心谨慎;该化合物一般都具有良好的调味,但潜在的副作用可能包括干嘴,眩晕和胃肠干扰;与任何药物一样,在保健专业人员的指导下使用脱氧苯丙胺至关重要,特别是在有前状况的个人或其他药物使用者.
- 英文名称Dexbrompheniramine
- 中文名称右溴苯那敏
- IUPAC名称(S)-3-(4-bromophenyl)-N,N-dimethyl-3-(pyridin-2-yl)propan-1-amine
- 其它别名2-Pyridinepropanamine,g-(4-bromophenyl)-N,N-dimethyl-,(S)-; Pyridine, 2-[p-bromo-a-[2-(dimethylamino)ethyl]benzyl]-, (S)- (8CI); (+)-2-[p-Bromo-a-[2-(dimethylamino)ethyl]benzyl]pyridine; (+)-Brompheniramine; (+)-Parabromdylamine; Dexbrompheniramine; d-Brompheniramine
- CAS编号132-21-8
- MFCD编号:MFCD00865678
- EINECS号:205-053-5
- FDA UNII编号:75T64B71RP
- 分子式:C16H19BrN2分子量:319.24
- 产品CID: 488262
- 同类组份化合物CAS980-71-2 (maleate)86-22-6 (free base)32656-44-3 (free base R-isomer)132-21-8 (free base S-isomer)2391-03-9 (maleate S-isomer)
- 产品分类原料药 → 抗变态反应药 → 抗组胺药
物理性质
- 熔点113-115
- 沸点403 °C at 760mmHg
- 闪点197.5 °C
- 密度1.265g/cm3
- PH:D25 +42.7° (c = 1 in DMF)
- pKa:pKa 9.3 (Uncertain)
- PSA:16.13
- LogP:3.92770
- 折射率1.577
- 蒸汽压1.05E-06mmHg at 25°C
- 溶解性1.27e-02 g/L
- 外观形态固体-粉末
- 储存条件Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
- 产品应用该化合物是一种抗脑膜胺,具有抗胆碱性,用于治疗干燥热或泌尿素等过敏性条件,是溴苯胺的药物活性脱氧异构体.
MSDS等安全信息
上下游产品
2-(4-bromobenzyl)pyridine 2-(dimethylamino)ethyl chloride 2-(4-Bromo-phenyl)-4-dimethylamino-2-pyridin-2-yl-butyronitrile 2-(4-Bromo-phenyl)-4-dimethylamino-butyronitrile合成工艺路线路线简述
海关参考信息
- 2902600000-乙苯
2933310010-吡啶
2921199090-其他无环单胺
2939800000-其他生物碱 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:WO-2023075715-A1
优先权日:2021-10-26
标题 :A pharmaceutical formulation including leukotriene receptor antagonists and/or leukotriene synthesis inhibitors combined with non-steroidal anti-inflammatory drugs (nsaids)
发明人：OYTUN FARUK; CAN EFE
权利人:VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI
摘要:This invention is related to a pharmaceutical formulation including Leukotriene receptor antagonists and/or Leukotriene synthesis inhibitors combined with non-steroidal anti-inflammatory drugs (NSAIDs) and antihistamines in ocular diseases and in inflammatory and allergic diseases for systemic and topical use. The objective of this invention is to create a novel formulation to be effective as much as steroids while having significantly less side effects for long-term use in treating ocular diseases, inflammatory and allergic diseases. In other words our aim is to achieve the inhibition of pro-inflammatory mediators (prostaglandins, thromboxane, histamine and leukotrienes) as much as steroids do with a safer combination.
专利号:CN-111138350-B
优先权日:2020-01-03
标题 :A kind of asymmetric synthesis method of dexchlorpheniramine and dexbrompheniramine
专利号:CN-111138350-A
优先权日:2020-01-03
标 题:Asymmetric synthesis method of dexchlorpheniramine and dexbrompheniramine
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Dexbrompheniramine. 2018 Oct 31. 74(1):25-8. doi: 10.1002/jps.2600740107. 34(10):681-93. doi: 10.1080/01902140802339623. 31(3):223-6. doi: 10.1111/j.1398-9995.1976.tb01682.x. 46(5):870-6. doi: 10.1016/j.jpba.2007.05.019. Epub 2007 May 25. 99(12):1477-84. doi: 10.1016/j.rmed.2005.09.039. 7(4):313-24. doi: 10.1089/jop.1991.7.313. 94(2):200.
22:324-8. 51(2):269-79. doi: 10.1016/s0039-9140(99)00256-8.
合成参考文献
参考文献:10.1007/s12272-012-1216-2
摘要:Jung KJ, Choi WH, Park SY, Lee SH, Yoo JS, Koh WS. Enhancement of B cell and monocyte populations in rats exposed to chlorpheniramine. Arch Pharm Res. 2012 Dec;35(12):2183–9. doi: 10.1007/s12272-012-1216-2.
📝 需求与反馈
尽可能描述清楚需求与问题信息
